141.65
-3.65 (-2.51%)
| Penutupan Terdahulu | 145.30 |
| Buka | 145.30 |
| Jumlah Dagangan | 1,898,569 |
| Purata Dagangan (3B) | 1,781,159 |
| Modal Pasaran | 21,771,603,968 |
| Harga / Pendapatan (P/E TTM) | 31.76 |
| Harga / Pendapatan (P/E Ke hadapan) | 25.91 |
| Harga / Jualan (P/S) | 4.77 |
| Harga / Buku (P/B) | 7.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Feb 2026 |
| Margin Keuntungan | -22.27% |
| Margin Operasi (TTM) | 17.67% |
| EPS Cair (TTM) | -6.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 110.09% |
| Nisbah Semasa (MRQ) | 1.86 |
| Aliran Tunai Operasi (OCF TTM) | 1.00 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 381.00 M |
| Pulangan Atas Aset (ROA TTM) | 4.96% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Illumina, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.80 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 0.19% |
| % Dimiliki oleh Institusi | 101.16% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 170.00 (Guggenheim, 20.01%) | Beli |
| 170.00 (Piper Sandler, 20.01%) | Beli | |
| Median | 150.00 (5.90%) | |
| Rendah | 110.00 (Barclays, -22.34%) | Jual |
| Purata | 145.00 (2.37%) | |
| Jumlah | 3 Beli, 3 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 139.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 09 Feb 2026 | 170.00 (20.01%) | Beli | 117.25 |
| JP Morgan | 06 Feb 2026 | 120.00 (-15.28%) | Pegang | 119.72 |
| 15 Dec 2025 | 130.00 (-8.22%) | Pegang | 134.92 | |
| Canaccord Genuity | 26 Jan 2026 | 150.00 (5.89%) | Pegang | 153.00 |
| 22 Dec 2025 | 130.00 (-8.22%) | Pegang | 137.60 | |
| Guggenheim | 26 Jan 2026 | 170.00 (20.01%) | Beli | 153.00 |
| 05 Jan 2026 | 144.00 (1.66%) | Beli | 141.33 | |
| Stifel | 20 Jan 2026 | 155.00 (9.42%) | Beli | 147.17 |
| TD Cowen | 07 Jan 2026 | 140.00 (-1.16%) | Pegang | 150.14 |
| Barclays | 15 Dec 2025 | 110.00 (-22.34%) | Jual | 134.92 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |